Research Article
BibTex RIS Cite
Year 2021, , 49 - 54, 31.03.2021
https://doi.org/10.7197/cmj.879083

Abstract

References

  • Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50. doi: 10.1016/j.diabres.2017.03.024
  • Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588
  • Pham SV, Chilton RJ. EMPA-REG OUTCOME: The Cardiologist's Point of View. Am J Cardiol. 2017 Jul 1;120(1S):S53-S58. DOI: 10.1016/j.amjcard.2017.05.011
  • Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008;41:567-74. doi: 10.1016/j.jelectrocard.2008.07.016
  • Ardahanli I, Celik M. Comparison of Tp-e interval, QTc interval and Tp-e/QTc ratios between non-diabetic and prediabetic population. Ann Med Res 2020;27(12):3117-22. doi: 10.5455/annalsmedres.2020.09.949
  • Tokatli A, Kiliçaslan F, Alis M, et al. Prolonged Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2016;31:105-12. doi: 10.3803/EnM.2016.31.1.105
  • Akhan O, Ardahanlı İ. Evaluation of Ventricular Polarization in Noncompaction Cardiomyopathy with Electrocardiography in a Different Perspective. ECM 2020;8(4):180-185. doi: 10.32596/ejcm.galenos.2020.08.044
  • Braschi A, Frasheri A, Lombardo RM, et al. Association between Tpeak-Tend/QT and major adverse cardiovascular events in patients with Takotsubo syndrome. Acta Cardiol. 2020 Jun 12:1-7. doi: 10.1080/00015385.2020.1776012
  • Ardahanli I, Akyuz O. The Effect of Hemodialysis Treatment on Ventricular Arrhythmogenesis Parameters in Electrocardiography. Selcuk Med J 2021;10.30733/std.2021.01491
  • Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020 Apr 14;141(15):1227-1234. DOI: 10.1161/CIRCULATIONAHA.119.044183
  • Kors JA, Ritsema van Eck HJ, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 2008; 41:575-80. doi: 10.1016/j.jelectrocard.2008.07.030
  • Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016 Nov 11;15(1):157. DOI: 10.1186/s12933-016-0473-7
  • Hashikata T, Ikutomi M, Jimba T, Shindo A, Kakuda N, Katsushika S, Yokoyama M, Kishi M, Sato T, Matsushita M, Ohnishi S, Yamasaki M. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes. Heart Vessels 2020; 35(10) :1378-89. doi:10.1007/s00380-020-01621-0
  • Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol. 2018 Nov 17;17(1):144. DOI: 10.1186/s12933-018-0790-0

Comparison of the effects of SGLT 2 inhibitors and sulfonylurea on electrocardiographic parameters

Year 2021, , 49 - 54, 31.03.2021
https://doi.org/10.7197/cmj.879083

Abstract

Objective: Tp-e, QT, and Tp-e / QT are parameters showing ventricular repolarization. The increase in these parameters causes an increase in cardiovascular mortality, mostly due to malignant arrhythmias. Our study aimed to compare the long-term changes in electrocardiographic parameters in patients with uncontrolled diabetes despite using metformin, with the addition of SGLT 2 inhibitor or sulfonylurea (SU) to the treatment.
Method: This retrospective study was enrolled in 133 type 2 DM patients with uncontrolled diabetes who applied to the internal medicine outpatient clinic, using single oral antidiabetic agents. The patients were divided into two groups as SU and SGLT 2 inhibitor additive. SU was added to the treatment of 69 patients, and SGLT 2 inhibitor was added to 64 patients. 12-lead superficial ECG records of participants who received combined therapy for at least six months were analyzed and compared. RR distance, QT interval, and Tp-e intervals were measured on the ECG. QTc was calculated using Bazzet's formula. (QT/ √ RR). Tp-e / QT and Tp-e / QTc ratios were calculated.
Results: Seventy-eight (58.6%) of the participants were female, and 55 (41.4) were male. The age and gender distribution of both groups were similar. The group to which SGLT 2 inhibitor was added, Tp-e, QT, and QTc distances were significantly lower than the SU group (p <0.001 for each). Also, the Tp-e / QT and Tp-e / QTc ratios were significantly greater in the SU group (0.210 ± 0.029 vs 0.190 ± 0.03; p <0.001 and 0.201 ± 0.051 vs 0.184 ± 0.032; p = 0.022 respectively).
Conclusions: In our study, we showed that the addition of SGLT2 inhibitors to monotherapy in people with diabetes with poor glycemic control has a positive effect on ECG parameters, which are indicators of repolarization, compared to other oral antidiabetics.

References

  • Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50. doi: 10.1016/j.diabres.2017.03.024
  • Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018 May 11;122(10):1439-1459. doi: 10.1161/CIRCRESAHA.117.311588
  • Pham SV, Chilton RJ. EMPA-REG OUTCOME: The Cardiologist's Point of View. Am J Cardiol. 2017 Jul 1;120(1S):S53-S58. DOI: 10.1016/j.amjcard.2017.05.011
  • Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol 2008;41:567-74. doi: 10.1016/j.jelectrocard.2008.07.016
  • Ardahanli I, Celik M. Comparison of Tp-e interval, QTc interval and Tp-e/QTc ratios between non-diabetic and prediabetic population. Ann Med Res 2020;27(12):3117-22. doi: 10.5455/annalsmedres.2020.09.949
  • Tokatli A, Kiliçaslan F, Alis M, et al. Prolonged Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio in patients with type 2 diabetes mellitus. Endocrinol Metab (Seoul) 2016;31:105-12. doi: 10.3803/EnM.2016.31.1.105
  • Akhan O, Ardahanlı İ. Evaluation of Ventricular Polarization in Noncompaction Cardiomyopathy with Electrocardiography in a Different Perspective. ECM 2020;8(4):180-185. doi: 10.32596/ejcm.galenos.2020.08.044
  • Braschi A, Frasheri A, Lombardo RM, et al. Association between Tpeak-Tend/QT and major adverse cardiovascular events in patients with Takotsubo syndrome. Acta Cardiol. 2020 Jun 12:1-7. doi: 10.1080/00015385.2020.1776012
  • Ardahanli I, Akyuz O. The Effect of Hemodialysis Treatment on Ventricular Arrhythmogenesis Parameters in Electrocardiography. Selcuk Med J 2021;10.30733/std.2021.01491
  • Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. Circulation. 2020 Apr 14;141(15):1227-1234. DOI: 10.1161/CIRCULATIONAHA.119.044183
  • Kors JA, Ritsema van Eck HJ, van Herpen G. The meaning of the Tp-Te interval and its diagnostic value. J Electrocardiol 2008; 41:575-80. doi: 10.1016/j.jelectrocard.2008.07.030
  • Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol. 2016 Nov 11;15(1):157. DOI: 10.1186/s12933-016-0473-7
  • Hashikata T, Ikutomi M, Jimba T, Shindo A, Kakuda N, Katsushika S, Yokoyama M, Kishi M, Sato T, Matsushita M, Ohnishi S, Yamasaki M. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes. Heart Vessels 2020; 35(10) :1378-89. doi:10.1007/s00380-020-01621-0
  • Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol. 2018 Nov 17;17(1):144. DOI: 10.1186/s12933-018-0790-0
There are 14 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Medical Science Research Articles
Authors

Onur Akhan 0000-0003-4440-9599

Ebru Şahin 0000-0002-2231-126X

Ramazan Aslan 0000-0002-1255-7880

Ahmet Aktaş 0000-0001-9464-0700

Publication Date March 31, 2021
Acceptance Date March 28, 2021
Published in Issue Year 2021

Cite

AMA Akhan O, Şahin E, Aslan R, Aktaş A. Comparison of the effects of SGLT 2 inhibitors and sulfonylurea on electrocardiographic parameters. CMJ. March 2021;43(1):49-54. doi:10.7197/cmj.879083